Xvivo Perfusion Earnings Call Highlights Growth And Margins

Xvivo Perfusion AB ((SE:XVIVO)) has held its Q1 earnings call. Read on for the main highlights of the call.

Xvivo Perfusion’s latest earnings call struck a confident tone, with management emphasizing record sales, double‑digit organic growth, and strengthening cash generation while acknowledging margin headwinds and regulatory dependencies. Investors heard a story of accelerating adoption in core technologies, notably EVLP and Heart Assist, underpinned by compelling clinical data and improving operational discipline.

Record Sales and Strong Top-Line Growth

Xvivo reported net sales of SEK 241 million for Q1 2026, describing it as a record quarter with broad-based momentum across its core franchises. Organic top-line growth reached 23%, or 18% when excluding contributions from the U.S. CAP trial, underscoring robust underlying demand rather than one-off trial-related revenue.

Profitability and Cash Flow

Profitability continued to improve, with EBITDA at 21% and underlying EBITDA at 24% when excluding SEK 7 million in nonrecurring heart go-to-market costs, while EBIT landed at 13%. Operating cash flow was solid at SEK 65 million and total cash flow was positive for a second consecutive quarter, leaving the company with SEK 308 million in cash at period end.

Thoracic Segment Outperformance

The thoracic segment was a standout performer, posting sales of SEK 160 million and organic growth of 27%, or 19% excluding CAP revenue, highlighting strong demand beyond clinical studies. Thoracic gross margin reached a high 83%, supported by price increases and favorable product mix, reinforcing the profitability of this core franchise.

EVLP Momentum and Hub Model

EVLP disposables surged 56% in Q1, reflecting growing clinical adoption and higher procedure volumes. A key driver was the successful OPO EVLP hub pilot, which completed 10 EVLPs, and a second OPO was onboarded in early Q2 with 4–5 more in the pipeline, supporting a scalable hub model to sustain future growth.

Kidney Sales Surge in Abdominal

In the abdominal segment, net sales reached SEK 66 million with 24% organic growth, demonstrating that the business is gaining traction despite margin pressure. Kidney sales were particularly strong, increasing 63% in local currencies as Kidney Assist Transport gained momentum in North America and new accounts came online.

Flowhawk Rapid Adoption

The Flowhawk software in the services segment delivered standout growth of 62% in Q1, underlining its strategic role as a digital tool for transplant programs. It is now implemented at six of the ten largest U.S. transplant centers, signaling strong enterprise-level adoption potential and a growing recurring revenue base.

Compelling Clinical Data for Heart

Management highlighted a powerful clinical package for its heart technology, with the U.S. PRESERVE trial meeting predefined efficacy and safety endpoints across 141 patients at 14 sites and showing a 7.9% severe PGD rate. European randomized data showed ex vivo perfusion cut severe PGD from 20% to 5% and improved one-year survival by 6%, while a DCD proof-of-concept study reported 98% 30-day survival and 5% severe PGD.

Regulatory and Market Access Progress

On market access, the heart machine and disposables have already received CE-marking, enabling initial compassionate-use sales in Europe and Australia. In the U.S., a regulatory submission for the heart system is being prepared for the FDA, while Liver Assist has Breakthrough Device status, an approved IDE, and CMS funding as the company prepares for further regulatory route discussions.

Services Segment Weakness in Organ Recovery

Not all parts of the business grew, with the services segment reporting net sales of SEK 60 million, a 10% organic decline. Organ recovery revenue fell 10% and gross margin dropped to 18%, in part because fixed 24/7 surgical-team costs are being spread over fewer cases, prompting management to focus on execution and volume ramp-up to restore profitability.

Abdominal Gross Margin Compression

Despite strong growth, abdominal gross margin fell to 54% from 63% a year earlier, reflecting a higher share of lower-margin kidney products and more exposure to lower-priced regions such as Asia, South America, and Eastern Europe. Ongoing manufacturing transitions and scaling also weighed on costs, though management expects improved leverage as volumes build.

Regulatory Timing and Commercialization Risk

The full commercial potential in heart and liver remains constrained by regulatory timelines, with some CE-mark steps still under review and U.S. approval timing uncertain. This dependency delays broader commercialization and reimbursement initiatives, introducing timing risk that could impact the pace of revenue ramp even as clinical data and early demand are strong.

Nonrecurring Costs and Investment Cash Outflow

Q1 results were impacted by SEK 7 million of nonrecurring go-to-market expenses for the heart franchise, elevating administrative costs but laying the groundwork for future launches. Cash flow from investments was negative SEK 55 million, reflecting continued spending on growth initiatives, R&D, and scaling infrastructure to support expected demand.

Service Margin Pressure from Scaling Surgical Teams

Margin pressure in services is also being driven by the need to maintain full surgical teams while case volumes are still building, depressing organ recovery profitability. Management stressed that the capacity and pipeline are in place, and that higher volumes will be crucial to spreading fixed costs and lifting margins over time.

EVLP Concentration Risk

EVLP growth, while impressive, has been partly driven by a handful of large customers and the pilot hub initiative, introducing a degree of concentration risk. A change in usage patterns at these key centers could create short-term revenue volatility, even though management points to a strong and diversifying pipeline for future EVLP adoption.

Currency and Regional Mix Impacts

The company’s overall gross margin stood at 71%, pressured by a weaker U.S. dollar, tariffs, and regional mix shifts toward lower-priced markets, especially in abdominal. While price increases have been used to offset some of these headwinds, the combination of FX, tariffs, and geographic mix remains a drag on margin expansion.

Forward-Looking Guidance and Strategic Priorities

Management expects the strong Q1 momentum to continue through 2026, aiming for full-year EBITDA near current market expectations and maintaining positive total cash flow. Priorities include submitting the U.S. heart file in summer, advancing CE work, rolling out 4–5 additional OPO EVLP hubs, expanding U.S. sales and surgical capacity, improving abdominal margins as volumes rise, and providing a liver regulatory update with the Q2 report.

Xvivo Perfusion’s earnings call painted a picture of a company transitioning from clinical validation to commercial scale, led by high-growth thoracic and digital offerings. While margin pressure in abdominal and services and regulatory timing risk remain, the combination of strong clinical evidence, accelerating adoption, and improving cash generation keeps the overall outlook constructive for investors watching the stock.